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Interferon (IFN) was discovered more than 50 years ago as an agent that inhibited the replication of influenza virus^[@CR1]^. The IFN family of cytokines is now recognized as a key component of the innate immune response and the first line of defence against viral infection. Accordingly, IFNs are currently used therapeutically, with the most noteworthy example being the treatment of hepatitis C virus (HCV) infection, and they are also used against various other disorders, including numerous malignancies and multiple sclerosis (reviewed in Ref. [@CR2]).

Three classes of IFN have been identified, designated types I to III, and are classified according to the receptor complex they signal through ([Fig. 1](#Fig1){ref-type="fig"}). The type II class of IFN comprises the single IFNγ gene product that binds the IFNγ receptor (IFNGR) complex, and mediates broad immune responses to pathogens other than viruses. The more recently described type III IFNs include three IFNλ gene products that signal through receptors containing IFNLR1 (IFNλ receptor 1; also known as IL-28Ra) and IL-10R2 (also known as IL-10Rβ). So far, little is known about the type III IFNs, although they are known to regulate the antiviral response and have been proposed to be the ancestral type I IFNs^[@CR3]^. Type I IFNs, which in humans comprise 13 IFNα subtypes, IFNβ, IFNκ, IFNɛ, IFNο, IFNτ and IFNδ, engage the ubiquitously expressed IFNAR (IFNα receptor) complex that is composed of IFNAR1 and IFNAR2. The function of type I IFNs is well characterized and they are known to be essential for mounting a robust host response against viral infection. Accordingly, IFNAR-deficient mice have increased susceptibility to numerous viruses but maintain resistance to other microbial pathogens, such as *Listeria monocytogenes*^[@CR4],[@CR5]^. Similarly, humans with genetic defects in components of the IFNR signalling pathway (STAT1 (signal transducer and activator of transcription 1), TYK2 (tyrosine kinase 2) or UNC93B) die of viral disease, with the defect in IFNAR (rather than IFNGR) signalling having the more significant role^[@CR6],[@CR7],[@CR8],[@CR9]^.Figure 1Interferon receptor signalling.The action of the interferons (IFNs) is mediated through three receptor complexes: a heterodimer of IFNα receptor 1 (IFNAR1) and IFNAR2 binds type I IFNs; the interleukin-10 receptor 2 (IL-10R2) associates with IFNLR1 (IFNλ receptor 1) to bind the three IFNλ subtypes; and a tetramer consisting of two IFNGR2 (IFNγ receptor 2) chains and two IFNGR1 chains binds dimers of the type II IFNγ. Following binding by type I IFNs, signal transduction is initiated by pre-associated tyrosine kinases (JAK1 and TYK2 (tyrosine kinase 2)), which phosphorylate IFNAR1 and leads to the recruitment and phosphorylation of the signal transducers and activators of transcription (STATs). STAT heterodimers associate with IFN-regulatory factor 9 (IRF9) to form IFN-stimulated gene factor 3 (ISGF3), or STAT homodimers to form the IFNγ activation factor (GAF). These complexes translocate to the nucleus to induce IFN-stimulated genes from IFN-stimulated response elements (ISREs) or GAS promoter elements, for type I and type III, or type II IFN responses, respectively. Divergence from this simplified signalling pathway can occur, for example, type I IFNs are reported to elicit STAT homodimers, and more complicated interplay, with activation of other STAT proteins, occurs than is shown here. ISG15, IFN-stimulated protein of 15 kDa; Mx, myxovirus resistance; OAS, 2′,5′-oligoadenylate synthetase; PKR, protein kinase R.

The binding of type I IFNs to the IFNAR initiates a signalling cascade, which leads to the induction of more than 300 IFN-stimulated genes (ISGs)^[@CR10]^. However, relatively few of these ISGs have been directly implicated in instigating the antiviral state. Instead, many of the gene products encode [pattern-recognition receptors](#Glos1){ref-type="list"} (PRRs) that detect viral molecules and modulate signalling pathways, or transcription factors that form an amplification loop resulting in increased IFN production and protection from virus spread to limit disease. Nevertheless, some ISGs encode proteins with potential for direct antiviral activity, including proteins that catalyse cytoskeletal remodelling, that induce apoptosis, that regulate post-transcriptional events (splicing, mRNA editing, RNA degradation and the multiple steps of protein translation) and proteins that are involved in subsequent post-translational modification. Indeed, several such proteins, ISG15 (IFN-stimulated protein of 15 kDa), the [GTPase](#Glos2){ref-type="list"} Mx1 (myxovirus resistance 1), ribonuclease L [(RNaseL)](#Glos3){ref-type="list"} and protein kinase R (PKR; also known as EIF2αK2), have been shown to function as antiviral effectors in studies of knockout mice. Mice with mutations or deficiencies in key steps of the pathways that are triggered by these proteins have increased susceptibility to viral infection.

In this Review, we summarize our current understanding of the role of ISG15, Mx1, RNaseL and PKR in the antiviral host immune response. However, although these four proteins are known to be important in the antiviral response, they do not represent the complete repertoire of antiviral effectors. Additional ISGs that probably also have important roles in antiviral activities include: the deaminases ADAR1 (adenosine deaminase, RNA-specific 1) and [APOBEC](#Glos4){ref-type="list"} (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide) proteins; the exonuclease ISG20; members of the tripartite-motif-containing (TRIM) proteins such as TRIM19 (also known as PML); the putative *S*-adenosyl-[L]{.smallcaps}-methionine viperin; and the highly IFN-induced translation regulators IFIT1 (IFN-induced protein with tetratricopeptide repeats 1) and IFIT2. All of these ISGs have been reported to function as antiviral proteins *in vitro* but further investigation using the appropriate gene knockout mouse models is needed for a better understanding of their relative importance in the antiviral response. In addition, responses elicited by IFN-induced microRNAs are just emerging as regulators of viral infection^[@CR11]^.

ISG15, the Mx proteins, the 2′,5′-oligoadenylate synthetase (OAS)-directed RNaseL pathway and PKR have varying responsiveness to type I IFNs: ISG15 is one of the most highly induced ISGs and, when coupled to protein substrates, it modulates numerous cellular activities; Mx proteins are also highly induced by type I IFNs and then assemble into oligomers that are constitutively active; OAS proteins are expressed at low levels in unstimulated cells, and are considerably induced by type I IFNs produced in response to viral RNA; and PKR is constitutively expressed as an inactive kinase that is activated by viral RNA, then further upregulated by type I IFNs. This variable responsiveness to IFN also underlies the function of each protein as solely an IFN effector, or as PRRs to enhance the IFN response.

**ISG15**

One of the most prominent ISGs to be induced during viral infection and the ensuing type I IFN response is the ∼15 kDa protein ISG15. Although the *ISG15* gene was cloned over 20 years ago^[@CR12]^, an antiviral function of the encoded protein has only recently been established and considerable work is still required to detail all of its actions and to resolve contradictory findings.

ISG15 was identified soon after the landmark discovery of [ubiquitin](#Glos5){ref-type="list"}, and was immediately recognized as a ubiquitin homologue^[@CR13]^ ([Fig. 2](#Fig2){ref-type="fig"}). Protein [ubiquitylation](#Glos6){ref-type="list"} regulates many aspects of the innate immune response, including intracellular signal transduction (for example, the activation of nuclear factor-κB (NF-κB)), and functions of the adaptive immune system, such as initiating tolerance (reviewed in Ref.[@CR14]). Given the importance of ubiquitylation in the immune response, it is perhaps not surprising that there is an IFN-regulated ubiquitin-like protein response. This response, as mediated by ISGs, is referred to as ISGylation.Figure 2Domain structure of antiviral proteins.**a** \| Interferon-stimulated protein of 15 kDa (ISG15) contains two ubiquitin-like (UBL) domains. The C-terminal UBL encodes conserved hydrophobic patches, charged pockets (indicated by vertical bars) and diglycine residues similar to ubiquitin and other ubiquitin-like proteins. Accordingly, the C-terminal UBL is sufficient for activation and transfer of ISG15 to E1 and E2 enzymes. However, the N-terminal UBL seems to be necessary for E3-mediated conjugation to protein substrates. **b** \| The distinguishing features of the dynamin protein family of Mx GTPases are the large GTP-binding domain (DYNc) that contains three consensus GTP-binding elements (not indicated) and a self-assembly sequence (SAS), the central interactive domain (CID), and the C-terminal leucine zipper (LZ). The LZ region contains a coiled-coil (CC) domain at its C terminus that forms bundles of α-helices involved in protein--protein interactions. **c** \| The 2′,5′-oligoadenylate synthetase 1 (OAS1), OAS2 and OAS3 proteins contain 1, 2 or 3 copies respectively, of the OAS domains. Duplicated OAS domains in OAS2 and OAS3, and the single domain in OASL (OAS-like) are catalytically inactive (shown in red). The C-termini of all the OAS proteins are variable, with OASL also encoding a unique UBL domain. The OAS domain produces 2′,5′-oligoadenylates that activate ribonuclease L (RNaseL). RNaseL has eight N-terminal ankyrin repeats (ANK), which mediate protein--protein interactions, and two kinase-like domains, a Ser/Thr/Tyr kinase (STYKc) and a PUG domain that are found in some kinases and several other nuclear proteins. However, neither domain has functional kinase activity. **d** \|Protein kinase R (PKR) contains two repeated RNA-binding motifs (RBMs), which together constitute the N-terminal RNA-binding domain. On binding of viral RNA, steric inhibition of enzyme activity is relieved, leading to the activation of the C-terminal serine/threonine protein kinase domain (S/T-kinase).

ISG15 is expressed as a 165 amino-acid precursor that is subsequently processed to expose the C-terminal sequence LRLRGG. The equivalent diglycine residues within this motif in ubiquitin are adenylated and conjugated by a thiolester bond to cysteine residues of three enzymes, a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase enzyme (E3), before being transferred to lysine residues on protein substrates. As the ubiquitin E1 enzyme (UBE1) is unable to form a thiolester bond with ISG15, ISGylation was initially thought to require a parallel and distinct pathway^[@CR15]^. However, having identified the enzymes that catalyse ISGylation, it is now becoming clear that there is direct interplay between ubiquitylation and ISGylation. The enzyme UBE1L (E1-like ubiquitin-activating enzyme) was shown to be the specific ISG15-activating enzyme (Ref. [@CR16]). Challenging this specificity, two E2 ubiquitin-conjugating enzymes, UBCH6 (also known as UBE2E1) and UBCH8 (also known as UBE2L6) were also shown to serve as ISG15 carriers^[@CR17],[@CR18]^. Downregulation of UBCH8 expression by [RNA interference](#Glos7){ref-type="list"} indicated that UBCH8 functions as the main E2 ISG15-conjugating enzyme in HeLa cells^[@CR19]^. Finally, two E3 ubiquitin ligases, HERC5 (homologous to the E6-associated protein C terminus (HECT) domain and RCC1-like domain containing protein 5) and TRIM25, have also been shown to conjugate ISG15 to protein substrates, through their respective HECT or RING (really interesting new gene) domains^[@CR20],[@CR21]^. Appropriately, all enzymes identified in the ISGylation pathway are coordinately induced by type I IFNs ([Fig. 3](#Fig3){ref-type="fig"}). As with ubiquitylation, ISGylation is reversible and several enzymes that catalyse the hydrolysis of ISG15 (termed deISGylation) have been identified, including ubiquitin-specific protease 18 (USP18, also known as UBP43), USP2, USP5, USP13 and USP14 (Refs [@CR22],[@CR23]).Figure 3Mechanism of action of ISG15.The expression of interferon (IFN)-stimulated protein of 15 kDa (ISG15), the E1-activating enzyme UBE1L (E1-like ubiquitin-activating enzyme) and multiple E2-conjugating enzymes (shown here as an example is UBCH8) and E3-ligase enzymes (such as HERC5 (homologous to the E6-associated protein C terminus domain and RCC1-like domain containing protein 5)) is coordinately induced by type I IFNs through IFN-stimulated response elements (ISREs) in their respective gene promoter regions. E1, E2 and E3 proteins sequentially catalyse the conjugation of ISG15 to numerous protein substrates to modulate pleiotropic cellular responses to inhibit virus production. This process (known as ISGylation) is reversibly regulated by proteases (such as ubiquitin-specific protease 18 (USP18)), which are also induced by IFNs.

At least 158 putative ISG15 target proteins have been identified so far^[@CR24],[@CR25],[@CR26]^. Many of these substrates have important roles in the type I IFN response, including the signalling components JAK1 (Janus kinase 1) and STAT1, the PRRs, such as RIG-I (retinoic-acid-inducible gene I), and the antiviral effector proteins MxA, PKR and RNaseL^[@CR24]^. Unlike ubiquitylation, ISGylation does not promote degradation of the target protein (as occurs following K48-linked ubiquitin), but instead parallels the activating effects of ubiquitylation (mediated by K63-linked ubiquitin). Accordingly, ISG15 has been reported to prevent virus-mediated degradation of IFN-regulatory factor 3 (IRF3), thereby increasing the induction of IFNβ expression^[@CR27]^. ISGylation has also been shown to modulate the function of enzymes. An example of this is the increased affinity of ISGylated eukaryotic translation initiation factor 4E family member 2 (EIF4E2; also known as 4EHP) for the 5′ cap structure of RNA^[@CR28]^. Conversely, conjugation of ISG15 to protein phosphatase 1B (PPM1B) suppressed the activity of this enzyme, thereby enhancing NF-κB signalling^[@CR29]^.

In addition to its intracellular role, ISG15 is secreted in large amounts and has been shown to act as a cytokine to modulate immune responses^[@CR30]^. The mechanism by which extracellular ISG15 functions is unresolved. Ubiquitin is also secreted from cells and has immunomodulatory effects that are not understood^[@CR31]^, although it might be involved in extracellular ubiquitylation, as suggested by analysis of surface proteins on spermatozoa during post-testicular maturation^[@CR32]^. It is therefore possible that secreted ISG15 might function in extracellular ISGylation, a possibility that could be tested by studying the effect of treating cells from *Ube1l*^*−/−*^ mice with ISG15.

Consistent with its designation as an antiviral protein, mice deficient in ISG15 have increased susceptibility to infection with several viruses, including the influenza A and B viruses, Sindbis virus, herpes simplex virus 1 (HSV-1) and murine γ-herpesvirus^[@CR33],[@CR34]^. In addition, infection of *Ifnar1*^*−/−*^ mice with a recombinant chimeric Sindbis virus expressing ISG15 protected against the Sindbis-virus-induced lethality that occurs following infection with wild-type virus^[@CR33]^. Compellingly, this protective effect of ISG15 expression required the conserved LRLRGG sequence at the C terminus of ISG15 (Ref. [@CR35]). In contrast to these reports, however, a similar chimeric ISG15-expressing Sindbis virus did not rescue *Ifnar1*^*−/−*^ mice from Sindbis-virus-induced lethality, although it did provide modest protection *in vitro*^[@CR36]^. Ablation of the deISGylation enzyme USP18 in mice increased their resistance to viral infection, notably to vesicular stomatitis virus (VSV) infection. However, the expected reciprocal increased sensitivity to VSV has not been observed in either *Isg15*^*−/−*^ or *Ube1l*^*−/−*^ mice^[@CR37]^. *Isg15*^*−/−*^ mouse embryonic fibroblasts were, however, more susceptible to VSV infection, although this sensitivity was lost after type I IFN treatment, suggesting that circulating IFNs *in vivo* may obscure some viral resistance mechanisms^[@CR27]^.

Other *in vitro* experiments support a role for ISG15 in mediating resistance to Ebola virus, through ISGylation of the E3 ubiquitin ligase NEDD4 (neural precursor cell expressed, developmentally downregulated 4), thereby blocking the activity of NEDD4 (Ref. [@CR38]). Similarly, ubiquitylation of the HIV-1 proteins Gag and Tsg101 is inhibited by ISG15 (Ref. [@CR39]). Ubiquitylation of NEDD4 and Gag or Tsg101 mediate the release of virions from cells. Further corroboration of an antiviral role for ISG15 comes from the identification of viral proteins that have evolved to target different steps of ISGylation. Nonstructural protein 1 (NS1) of influenza B virus binds ISG15 at the N-terminus and blocks ISGylation^[@CR16],[@CR40]^. Finally, several viral proteases from severe acute respiratory syndrome (SARS)-associated coronavirus, Crimean-Congo haemorrhagic fever virus, equine arteritis virus, porcine respiratory and reproductive syndrome virus, and Sindbis virus have been found to mediate deISGylation^[@CR41],[@CR42],[@CR43]^.

Therefore, an important role for ISGylation in the IFN-mediated antiviral response, through the modification of components of the host immune response or viruses, is emerging.

**Mx GTPases**

In addition to components of the ISGylation pathway, type I IFNs induce the expression of several guanine-hydrolysing proteins. This class of protein is involved in scission to mediate vesicle budding, organogenesis and cytokinesis. There is evidence that four families within this protein class are involved in host resistance to pathogens, and these include the p47 guanylate-binding proteins (GBPs), the p65 GBPs, the very large inducible GTPases and the Mx proteins^[@CR44]^. However, of these four protein families, only the Mx proteins have a well-characterized antiviral role and show a strict dependence on type I and III IFNs for their expression^[@CR45]^.

The Mx family GTPases, which comprise MxA and MxB in humans and Mx1 and Mx2 in mice, were first identified as antiviral proteins by the observation that the sensitivity of many inbred mouse strains to orthomyxomavirus was solely due to mutations within the *Mx* locus on chromosome 16 (Refs [@CR46],[@CR47],[@CR48]). This sensitivity could be rescued by restoration of Mx1 expression^[@CR49]^. Strikingly, constitutive expression of the human equivalent of mouse Mx1, MxA, in IFNAR-deficient mice confers full resistance to otherwise fatal infection with Thogoto virus, LaCrosse virus or Semliki Forest virus^[@CR49]^.

The two human Mx proteins are encoded on chromosome 21, in a region syngeneic to the Mx region on mouse chromosome 16 (Refs [@CR50],[@CR51]). The human proteins and mouse Mx2 are cytoplasmic, whereas mouse Mx1 localizes to the nucleus. This differential distribution in mice is thought to allow each protein to target viruses that replicate in either cell compartment^[@CR52]^. However, of the Mx family of proteins, only human MxA has been shown to have antiviral activity, and this is targeted against both nuclear and cytoplasmic viruses.

Viruses that are susceptible to the activities of Mx proteins include orthomyxomaviruses, paramyxomaviruses, rhabdoviruses, togaviruses and bunyaviruses. Similarly, human MxA has been shown to inhibit all infectious genera of the Bunyaviridae family (orthobunyavirus, hantavirus, phlebovirus and dugbe virus)^[@CR53]^. Members of other virus families, such as the clinically significant coxsackie virus (from the Picornaviridae family) and hepatitis B virus (HBV; from the Hepadnaviridae family) are also susceptible to human MxA antiviral activity^[@CR54],[@CR55]^. In addition, genetic studies of human populations have shown that a polymorphism in the *MXA* gene correlates with increased susceptibility to HCV^[@CR56]^, HBV57 and measles virus, with the latter associated with higher rates of subacute sclerosing panencephalitis^[@CR58]^. Appropriately, Mx proteins are expressed by various cell types in peripheral tissues, for example, by hepatocytes, endothelial cells and immune cells, including peripheral blood mononuclear cells, [plasmacytoid dendritic cells](#Glos8){ref-type="list"} and myeloid cells^[@CR59]^.

The Mx proteins have a large (relative to many other GTPases) N-terminal GTPase domain, a central interacting domain (CID) and a C-terminal leucine zipper (LZ) domain ([Fig. 2](#Fig2){ref-type="fig"}). Both the CID and the LZ domain are required to recognize target viral structures. The main viral target seems to be viral nucleocapsid-like structures^[@CR60]^. By virtue of their location near the smooth endoplasmic reticulum, Mx proteins can survey exocytic events and mediate vesicle trafficking to trap essential viral components, and in so doing, they prevent viral replication at early time points^[@CR61]^ ([Fig. 4](#Fig4){ref-type="fig"}). Both MxA and Mx1 associate with subunits of the influenza virus polymerase (PB2 and nucleocapsid protein) to block viral gene transcription^[@CR62]^. This is a potent antiviral measure, which effectively prevents the generation of viral mutants that escape Mx-mediated antiviral mechanisms. As a result, few viral countermeasures against Mx proteins have been identified.Figure 4Mechanism of action of MxA.Following stimulation with type I interferons (IFNs), *MXA* (myxovirus-resistance A) gene expression is induced through an IFN-stimulated response element (ISRE) in the gene promoter. The MxA protein accumulates in the cytoplasm on intracellular membranes (such as the endoplasmic reticulum, ER) as oligomers formed by association between the leucine zipper (LZ) domain and central interactive domain of the protein. Following viral infection, MxA monomers are released and bind viral nucleocapsids or other viral components, to trap and then degrade them.

Most viral escape mechanisms that have been described target type I IFN signalling: for example, highly virulent strains of influenza virus increase their replicative fitness to effectively \'out run\' the IFN response^[@CR63]^. More directly, the HBV precore or core protein has been reported to interact with the *MXA* promoter to prevent *MXA* gene expression^[@CR64]^. Also, West Nile virus (WNV) produces what seem to be decoy cytoplasmic membrane structures that \'hide\' crucial viral replication components from Mx proteins^[@CR65]^.

In contrast to ISG15 and Mx, the OAS and RNaseL pathway and PKR are expressed ubiquitously at low levels but their level of expression can be increased by exposure to type I IFNs. Constitutive levels of OAS and PKR mean that these proteins function not only as effector proteins but also as double-stranded RNA (dsRNA)-specific PRRs to trigger the antiviral response.

**The OAS and RNaseL pathway**

Initially identified as IFN-induced proteins that generate low-molecular-weight inhibitors of cell-free protein synthesis, the OAS proteins are distinguished by their capacity to synthesize 2′,5′-linked phosphodiester bonds to polymerize ATP into oligomers of adenosine^[@CR66],[@CR67]^. These unique 2′,5′-oligomers specifically activate the latent form of RNaseL, which can then mediate RNA degradation^[@CR68]^. In this way, OAS in combination with RNaseL constitutes an antiviral RNA decay pathway. As the OAS proteins are constitutively expressed at low levels, they can act as PRRs for the detection of viral dsRNA in the cytoplasm^[@CR65]^. RNA degraded by RNaseL can activate the other cytoplasmic PRRs, such as RIG-I and MDA5 (melanoma differentiation-associated gene 5), resulting in the induction of type I IFN gene expression. This accounts for the observation that RNaseL-deficient cells show markedly decreased IFNβ production owing to reduced signalling through these PRRs^[@CR69]^.

The four OAS genes identified in humans, termed *OAS1*, *OAS2*, *OAS3* and *OASL* (OAS-like), have been mapped to chromosome 12 (chromosome 5 in mice) (reviewed in Ref. [@CR70]). *OAS1* has two spliced forms in humans (eight in mice) that produce two proteins of 40 and 46 kDa that differ at their C termini by 18 and 54 amino acids, respectively. *OAS2* produces four alternatively spliced transcripts that encode two proteins of 69 and 71 kDa. *OAS3* encodes a single transcript that produces a 100 kDa protein. These proteins have considerable homology to each other, with OAS1, OAS2 and OAS3 encoding one, two and three OAS domains, respectively ([Fig. 2](#Fig2){ref-type="fig"}). The most distinctive of the OAS proteins is OASL. Two *OASL* transcripts are expressed, which produce two proteins of 30 and 59 kDa. The higher molecular weight OASL protein contains a putative nuclear-localization signal (RKVKEKIRRTR) at its C terminus that probably accounts for its unique distribution in the cell compared with the other OAS isoforms. The OASL protein also has an OAS domain, but mutations at key residues disable its catalytic function. Interestingly, one of the two mouse homologues of OASL retains its 2′,5′-polymerase activity. In addition to the OAS domain, OASL has a unique 160 amino-acid C terminus that encodes a ubiquitin-like domain that is homologous to ISG15. Accordingly, OASL becomes conjugated through ISGylation to cellular proteins following the treatment of cells with type I IFNs^[@CR71]^.

There seems to be differential expression and induction of each form of the human OAS proteins^[@CR72]^. Also, each of the three functional OAS proteins has unique biological functions. A tripeptide motif (CFK) within the OAS domains of OAS1 and OAS2 mediates oligomerization, so the catalytically active form of these enzymes is a tetramer and dimer for OAS1 and OAS2, respectively^[@CR73]^. This tripeptide motif is not conserved in the OAS domains of OAS3 and OASL and therefore these proteins function as monomers. The polymerization of OAS monomers influences their processivity; OAS3 synthesizes dimeric molecules of 2′,5′-linked oligomers, whereas OAS1 and OAS2 can synthesize trimeric and tetrameric oligomers^[@CR74],[@CR75]^. The dimeric 2′,5′-linked oligomers are not efficient activators of RNaseL^[@CR76]^ and, consequently, are thought to regulate alternative processes, with one report suggesting a role in gene expression by regulating DNA topoisomerase I^[@CR77]^.

The 2′,5′-dependent RNaseL is expressed as an 80 kDa protein with two kinase-like domains (PUG and STYKc) and eight ankyrin repeats ([Fig. 2](#Fig2){ref-type="fig"}) (reviewed in Ref. [@CR78]). The enzyme is constitutively expressed as an inactive monomer and is activated through binding of 2′,5′-linked oligomers (generated by OAS proteins) to the ankyrin repeats, which subsequently leads to homodimerization^[@CR79]^. The active dimeric enzyme then degrades single-stranded RNA (ssRNA)^[@CR80],[@CR81]^ ([Fig. 5](#Fig5){ref-type="fig"}). Owing to their perceived common effect on RNaseL, the antiviral function of the OAS proteins has been investigated using RNaseL-deficient mice^[@CR82]^. These mice show increased susceptibility to RNA viruses from the Picornaviridae, Reoviridae, Togaviridae, Paramyxoviridae, Orthomyxoviridae, Flaviviridae and Retroviridae families^[@CR78]^. An antiviral role for RNaseL against DNA viruses is less directly established, although as these viruses produce dsRNA replicative intermediates they can induce the production of 2′,5′-linked oligomers. However, activation of RNaseL following binding of 2′,5′-linked oligomers is less commonly observed in response to DNA viruses, presumably because of virally encoded inhibitory factors, such as the E3L protein from vaccinia virus^[@CR83]^. The direct importance of OAS proteins in the antiviral response in humans is highlighted by genetic studies showing that polymorphisms within a splice-acceptor site of the *OAS1* gene (producing two isoforms of the enzyme with different activities) significantly correlate with the antiviral response to the yellow fever vaccine in immunization clinical trials^[@CR84]^.Figure 5The OAS1--RNaseL antiviral pathway.2′,5′-oligoadenylate synthetase 1 (OAS1) is expressed at low constitutive levels and is upregulated by type I interferons (IFNs). OAS1 protein accumulates in the cell cytoplasm as an inactive monomer. Following activation by viral double-stranded RNA (dsRNA), the enzyme oligomerizes to form a tetramer that synthesizes 2′,5′-oligoadenylates that, in turn, activate the constitutively expressed inactive ribonuclease L (RNaseL). The binding of 2′,5′-oligoadenylates to RNaseL triggers the dimerization of enzyme monomers, through their kinase-like domains, and this then enables RNAseL to cleave cellular (and viral) RNAs. ISRE, IFN-stimulated response element.

It has recently become apparent that the OAS proteins have additional antiviral functions that are independent of RNaseL activity. The precise mechanisms of RNaseL independence remain to be elucidated. Nevertheless, single nucleotide polymorphisms (SNPs) at a splice enhancer site in OASL have been correlated with susceptibility to infection with WNV^[@CR85]^. Intriguingly, the capacity to accept GTP implies a potential role for OAS in RNA splicing, whereby the enzyme generates a 2′,5′-phosphodiester bond between the guanine at the 5′ end of an intron, and the adenine of a 3′ splice signal in the splicing intermediate structure^[@CR86]^.

**PKR**

Similar to OAS, PKR was initially identified as a regulator of the antiviral response through studies of protein synthesis in cell-free lysates from IFN- and dsRNA-treated cells^[@CR66],[@CR87]^. PKR belongs to a small family of protein kinases that respond to environmental stresses to regulate protein synthesis (the other members are EIF2αΚ1 (also known as HRI), EIF2αK3 (also known as PERK) and EIF2αK4 (also known as GCN2)). Members of this kinase family phosphorylate EIF2α at serine residue 51, resulting in sequestration of the limiting guanine-nucleotide exchange factor EIF2β (Ref. [@CR88]). This prevents recycling of GDP, halting translation, and therefore allows the cell to reconfigure gene expression. Much of the antiviral and antiproliferative activities of PKR can be attributed to its phosphorylation of EIF2α. Moreover, structural determination of the complex of EIF2α and PKR argues against the existence of alternative substrates^[@CR89]^. However, there is extensive biological and biochemical evidence for alternative PKR targets, although the consequences of PKR-mediated phosphoregulation of other proteins have not been well characterized. As well as directly regulating proteins by phosphorylation, PKR induces cellular responses by modulating cell-signalling pathways (discussed below).

PKR is constitutively expressed in all tissues at a basal level and is upregulated by type I and type III IFNs^[@CR90]^. Under normal circumstances, PKR is maintained as an inactive monomer, through steric hindrance of the kinase domain by its N terminus^[@CR91],[@CR92]^ ([Fig. 2](#Fig2){ref-type="fig"}). This repression is released by activating ligands, including viral RNAs, polyanionic molecules such as heparin^[@CR93]^ or ceramide^[@CR94]^, and protein activators^[@CR95]^, which elicit a conformational change that allows binding of ATP to the C-terminal kinase domain. The kinase domain consists of two lobes that separately regulate the interaction between protein monomers and the substrate. The active PKR enzyme consists of a homodimer orientated in a parallel, back-to-back arrangement, with the active sites of the enzyme facing outwards^[@CR89]^. Dimerization induces, and requires, autophosphorylation at several key residues^[@CR96],[@CR97],[@CR98]^. Activation of PKR following dimerization then leads to the phosphorylation of EIF2α to halt translation ([Fig. 6](#Fig6){ref-type="fig"}).Figure 6Mechanism of action of PKR.Protein kinase R (PKR) is constitutively expressed, and is also induced by type I interferons (IFNs) under the control of a kinase conserved sequence (KCS) and IFN-stimulated response element (ISRE) in the promoter of *PKR*. The kinase accumulates in the nucleus and cytoplasm as an inactive monomer, which is activated directly by viral RNAs, and by several other ligands, such as ceramide or the protein activator PACT (protein activator of the IFN-inducible protein kinase). Following activation, PKR monomers are phosphorylated and dimerize to form the active enzyme. Activated PKR regulates several cell signalling pathways through mechanisms that have not been fully explained, but a crucial function of PKR in viral defence is the inhibition of translation by phosphorylation of eukaryotic translation initiation factor 2α (EIF2α).

Direct activation of PKR has been shown with various RNAs by virtue of the two RNA-binding motifs (RBMs) in the N-terminal of PKR. All RBMs that have been tested bind dsRNA independently of sequence, but recognize a specific higher ordered structure. Accordingly, PKR, similar to the OAS--RNaseL pathway, functions as a PRR. Although RBMs have been shown to bind to just 16 base pairs of RNA, longer RNA moieties are required to engage both of the RBMs in PKR and to activate the kinase function^[@CR99]^. Consequently, dsRNA that is longer than 30 base pairs activates PKR most effectively. Also, ssRNAs of 47 bases that have limited ternary structure activate the kinase if they contain 5′-triphosphates^[@CR100]^. As cellular RNA transcripts predominantly have 5′-monophosphates, this enables PKR to specifically target viral RNAs.

Other pathogen-associated molecules, such as lipopolysaccharide (LPS), which is a ligand of Toll-like receptor 4 (TLR4), can also activate PKR^[@CR101]^, but this is probably indirect activation via another protein. Indeed, three key protein interactions have been identified. PKR interacts with the tumour-necrosis factor [(TNF)-receptor-associated factor (TRAF) family](#Glos9){ref-type="list"} of adaptor molecules that are integral to TLR signalling pathways^[@CR102]^. The protein activator of PKR PACT (protein activator of the IFN-inducible protein kinase; also known as PRKRA) responds to stress-inducing molecules, such as hydrogen peroxide, ceramide and cytokines (including IFNγ, IL-3 and TNF)^[@CR95]^. However, the consequences of activation of PKR by PACT in an antiviral context awaits the characterization of PACT-deficient mice. Finally, PKR can be activated by cleavage of its inhibitory N terminus by caspases (caspase-3, caspase-7 and caspase-8), which generate a constitutively active, truncated, kinase domain^[@CR103],[@CR104]^.

The role of PKR in antiviral responses has been investigated in mutant and transgenic mouse models. Mice expressing PKR with deletion mutations that target both functional domains of the enzyme^[@CR105],[@CR106]^, transgenic mice expressing a trans-dominant negative mutant of human PKR that is defective in kinase activity (Lys296Arg)^[@CR107]^, and transgenic mice overexpressing wild-type human PKR, have all been generated^[@CR108]^. These transgenic mice have impaired antiviral responses and show increased susceptibility to otherwise innocuous infections with viruses, such as VSV^[@CR109],[@CR110]^, influenza virus and bunyawera virus^[@CR111]^. Experiments in PKR-deficient mouse embryonic fibroblasts show that PKR is involved in protection against infection with several RNA viruses, including HCV^[@CR112]^, hepatitis D virus^[@CR113]^, WNV^[@CR114]^, HIV-1 (Ref. [@CR115]), Sindbis virus^[@CR116]^, encephalomyocarditis virus^[@CR117]^, and foot-and-mouth disease virus^[@CR118]^, as well as some DNA viruses such as HSV-1 (Ref. [@CR119]). As with MxA and OAS1, genetic analysis of human populations show that polymorphisms in the *PKR* gene correlate with the outcome of HCV infection^[@CR120]^.

**Additional immune functions**

Studies of the ISG15, OAS--RNaseL and PKR pathways suggest additional functions for each of these proteins. The main activating enzyme in ISGylation, UBE1L, was shown to be deleted in almost all small-cell lung cancers, and so the gene product was speculated to be a tumour suppressor^[@CR121],[@CR122]^. Given the specificity of UBE1L in ISGylation, this presents an intriguing possible mechanism by which type I IFNs could regulate proliferation.

RNaseL-deficient mice have an enlarged thymus and spleen due to suppressed apoptosis^[@CR82]^. The significance of the ability of RNaseL to induce apoptosis has been illustrated by genetic analysis that identified a polymorphism that generates an amino-acid substitution at position 462 (Arg462Gly) that was associated with reduced enzyme activity and increased incidence of prostate cancer^[@CR123]^. Intriguingly, this SNP was then shown to be associated with a putative oncolytic xenotropic murine leukaemia-related virus^[@CR124]^. Other nonviral functions of RNaseL are implied in experiments that show delayed skin-graft rejection in RNaseL-deficient mice^[@CR125]^. A polymorphism identified in *OAS1* has also been associated with type I diabetes, which is consistent with a viral aetiology for this disease^[@CR126],[@CR127]^.

Given that PKR modulates several signalling pathways, a broader function than that determined solely by regulation of translation would be expected. As mentioned above, PKR is required for TLR4-mediated apoptosis in macrophages. Although PKR-mediated apoptosis is in part attributable to inhibition of translation through EIF2α phosphorylation, alternative signalling through IRF3 is also important^[@CR101]^. PKR also promotes degradation of the inhibitor IκB, thereby activating the potent transcription factor NF-κB^[@CR128]^. Regulation of NF-κB by PKR accounts for the diminished expression of nitric-oxide synthase 2 and IFNβ by PKR-deficient cells^[@CR129]^. In addition, PKR was shown to be required for LPS-induced STAT-mediated inflammatory signalling^[@CR130]^. There is also a defect in IFN-induced phosphorylation of serine 727 in STAT1 (Ref. [@CR131]), which was shown to be necessary for the basal expression of caspase-3. Accordingly, PKR-deficient fibroblasts are variably resistant to apoptosis that is induced by different stimuli, including dsRNA, LPS and TNF^[@CR132]^. Conversely, overexpression of PKR in NIH3T3 fibroblasts sensitizes them to apoptosis^[@CR103]^. PKR may also influence the adaptive immune response by negatively regulating CD8^+^ T-cell function, as PKR-deficient mice have increased contact hypersensitivity responses and stimulus-dependent T-cell proliferation^[@CR133]^. PKR has also been implicated in IgE class switching in B cells. This points to a mechanism by which viral infection might induce IgE-mediated disorders, such as allergy and asthma^[@CR134],[@CR135]^. Surprisingly, these signalling events are not wholly mediated by direct phosphorylation by PKR, suggesting that it might act as a scaffold to bridge signalling pathways from alternative PRRs^[@CR136]^. The mechanisms underlying these links to adaptive immunity are intriguing but remain to be explained.

**Concluding remarks and future directions**

The analyses of mice with targeted deletions in the genes encoding ISG15, Mx1, PKR and RNaseL have helped to elucidate specific roles for the gene products in the antiviral response. Further details of the mechanisms of action of each of these effectors are still to be elucidated. Considerable work is still required to decipher the processes of ISGylation, to characterize protein substrates and to detail the consequence for the antiviral response. Also, the precise function of the Mx proteins remains uncertain. The contribution of alternative PKR substrates (besides EIF2α) to the immune response is poorly explored, and questions remain about specific roles for PKR in regulating inflammatory responses, in particular whether this requires kinase function or its putative role as an adaptor protein. The precise roles of the different OAS proteins, especially relating to RNaseL-independent antiviral effects, are ill-defined. These alternative functions will be better addressed *in vivo* by the analysis of mice with more subtle targeted mutations, and *in vitro* by detailed biochemical analyses (for example, by identification of specific phosphorylation sites on substrates for PKR) and by more detailed structural investigation of the mechanism of activation of each protein.

Strategies used by viruses to escape these antiviral pathways are also informative and a large number of viral countermeasures to block ISG15, PKR, RNaseL and Mx have been reported (reviewed in Refs [@CR78],[@CR137],[@CR138]). It should be noted, however, that many of the mechanisms attributed to virus-evolved avoidance of antiviral effectors and enhanced virulence have not been rigorously proven. An exception to this is the mechanism used by the HSV-1 protein ICP34.5 for targeting PKR. In this case, a virus that has been attenuated by the deletion of ICP34.5 only replicates as efficiently as wild-type virus when it infects PKR-deficient mice. Restoration of virulence was shown to depend on ICP34.5 by using both host and viral mutants^[@CR139]^. Although this approach is not trivial to replicate, it remains the most valid method for defining effective viral avoidance of type I IFN activity.

Another important approach currently underway is to catalogue SNPs in each of these genetic loci in human populations and other animal species. Correlation of genetic polymorphisms in putative antiviral genes with susceptibility to viruses, as well as with incidence of other immune responses, is emerging as a powerful means of confirming gene function and measuring their contribution to disease.

Finally, the most interesting developments in this field are likely to come from further insights into the broader role of each of these antiviral proteins, particularly in mediating adaptive immunity. Although the mechanisms underlying these links to adaptive immunity are yet to be explained, progress in this area has great potential to manipulate immunity and therefore to enhance resistance to pathogens and disease or, alternatively, to diminish deleterious autoimmune responses. This will probably also require parallel advancement in our understanding of the specificities of type I and type III IFN signalling.
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Pattern-recognition receptors

:   (PRRs). Host receptors that can sense pathogen-associated molecular patterns and initiate signalling cascades that lead to an innate immune response. These can be membrane bound (such as Toll-like receptors) or soluble cytoplasmic receptors (such as RIG-I, MDA5 and NLRs).

GTPase

:   A signalling protein that binds guanine nucleotides. A GTPase is active in the GTP-bound state and is inactivated when it hydrolyses GTP into GDP.

RNaseL

:   (Ribonuclease L). A constitutively expressed, latent, nonspecific endoribonuclease that is activated by 2′,5′-oligoadenylate. Type I interferons induce RNaseL expression as part of the host antiviral response.

APOBEC

:   (Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide). A cytidine deaminase enzyme family that includes: APOBEC1, an RNA editor involved in lipid metabolism; APOBEC3G and APOBEC3F, two DNA editors with antiretroviral activity; and activation-induced cytidine deaminase (AID), a DNA editor mediating immunoglobulin gene diversification.

Ubiquitin

:   A small protein that is attached to other proteins by ubiquitin ligases. Depending on the mode of attachment, ubiquitin can either activate signalling function or target a protein for destruction by the proteasome.

Ubiquitylation

:   The attachment of the small protein ubiquitin to lysine residues that are present in other proteins. Protein ubiquitylation occurs in three enzymatic steps requiring a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3), which catalyses the ligation of an isopeptide bond between the C-terminal domain of ubiquitin and an amino group belonging to a lysine residue of the target protein.

RNA interference

:   The use of double-stranded RNAs with sequences that match a given gene, to \'knockdown\' the expression of that gene by directing RNA-degrading enzymes to destroy the encoded mRNA transcript.

Plasmacytoid dendritic cells

:   (pDCs). A unique family of dendritic cells with a morphology that resembles that of a plasmablast. These cells are also known as interferon (IFN)-producing cells because they are the main source of type I IFNs during viral infections.

TNF-receptor-associated factor family

:   (TRAF family). A family of conserved scaffold proteins that link receptors of the tumour-necrosis factor (TNF) and Toll/interleukin-1 receptor family to various protein kinases (such as IRAK1). These proteins encode RING domains that, by association with E3-ubiquitin ligases, catalyse polyubiquitylation of proteins (such as IKKs to activate the transcription factor NF-κB) to transduce signals in the cell.
